Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adalimumab on Preventing Postoperative Recurrence of Crohn's Disease

NCT01564823 is registered in ClinicalTrials.gov with Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa as lead sponsor.

NCT NCT01564823
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01564823 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adalimumab on Preventing Postoperative Recurrence of Crohn's Disease
Lead sponsor
Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2012
Completion date
January 31, 2015
Enrollment
86 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

crohn´s disease